{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T13:46:17Z","timestamp":1774705577112,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2008,8,6]],"date-time":"2008-08-06T00:00:00Z","timestamp":1217980800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1007\/s00228-008-0534-2","type":"journal-article","created":{"date-parts":[[2008,8,5]],"date-time":"2008-08-05T01:55:39Z","timestamp":1217901339000},"page":"961-966","source":"Crossref","is-referenced-by-count":7,"title":["Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects"],"prefix":"10.1007","volume":"64","author":[{"given":"Luis","family":"Almeida","sequence":"first","affiliation":[]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"given":"Manuel","family":"Vaz-da-Silva","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Nunes","sequence":"additional","affiliation":[]},{"given":"Ana-Teresa","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9-Francisco","family":"Rocha","sequence":"additional","affiliation":[]},{"given":"Carla","family":"Neta","sequence":"additional","affiliation":[]},{"given":"Tice","family":"Macedo","sequence":"additional","affiliation":[]},{"given":"C.","family":"Fontes-Ribeiro","sequence":"additional","affiliation":[]},{"given":"P.","family":"Soares-da-Silva","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2008,8,6]]},"reference":[{"key":"534_CR1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1177\/0091270003258666","volume":"43","author":"L Almeida","year":"2003","unstructured":"Almeida L, Soares-da-Silva P (2003) Pharmacokinetic and pharmacodynamic profiles of BIA 3\u2013202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects. J Clin Pharmacol 43:1350\u20131360","journal-title":"J Clin Pharmacol"},{"key":"534_CR2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/wnf.0b013e3180645cb0","volume":"31","author":"J Ferreira","year":"2008","unstructured":"Ferreira J, Almeida L, Cunha L, Ticmeanu M, Rosa MM, Janu\u00e1rio C, Mitu C-E, Coelho M, Correia-Guedes L, Morgadinho A, Nunes T, Wright LC, Falc\u00e3o A, Sampaio C, Soares-da-Silva P (2008) Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase (COMT) activity and motor fluctuations in patients with Parkinson\u2019s disease. Clin Neuropharmacol 31:2\u201318","journal-title":"Clin Neuropharmacol"},{"key":"534_CR3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00002826-200401000-00007","volume":"27","author":"L Almeida","year":"2004","unstructured":"Almeida L, Vaz-da-Silva M, Silveira P, Falcao A, Maia J, Loureiro A, Torrao L, Machado R, Wright L, Soares-da-Silva P (2004) Pharmacokinetic-pharmacodynamic interaction between BIA 3\u2013202, a novel COMT inhibitor, and levodopa\/carbidopa. Clin Neuropharmacol 27:17\u201324","journal-title":"Clin Neuropharmacol"},{"key":"534_CR4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00228-003-0680-5","volume":"59","author":"P Silveira","year":"2003","unstructured":"Silveira P, Vaz-Da-Silva M, Almeida L, Maia J, Falcao A, Loureiro A, Torrao L, Machado R, Wright L, Soares-Da-Silva P (2003) Pharmacokinetic-pharmacodynamic interaction between BIA 3\u2013202, a novel COMT inhibitor, and levodopa\/benserazide. Eur J Clin Pharmacol 59:603\u2013609","journal-title":"Eur J Clin Pharmacol"},{"key":"534_CR5","doi-asserted-by":"crossref","first-page":"22S","DOI":"10.1378\/chest.119.1_suppl.22S","volume":"119","author":"J Ansell","year":"2001","unstructured":"Ansell J, Hirsh J, Dalen J (2001) Managing oral anticoagulant therapy. Chest 119:22S\u201338S","journal-title":"Chest"},{"key":"534_CR6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/0091270004271404","volume":"45","author":"DJ Greenblatt","year":"2005","unstructured":"Greenblatt DJ, von Moltke LL (2005) Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 45:127\u2013132","journal-title":"J Clin Pharmacol"},{"key":"534_CR7","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/cpt1976195part1552","volume":"19","author":"A Yacobi","year":"1976","unstructured":"Yacobi A, Udall JA, Levy G (1976) Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin Pharmacol Ther 19:552\u2013558","journal-title":"Clin Pharmacol Ther"},{"key":"534_CR8","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2165\/00003088-199630060-00002","volume":"30","author":"S Harder","year":"1996","unstructured":"Harder S, Thurmann P (1996) Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 30:416\u2013444","journal-title":"Clin Pharmacokinet"},{"key":"534_CR9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/j.1875-9114.1997.tb03782.x","volume":"17","author":"JS Cropp","year":"1997","unstructured":"Cropp JS, Bussey HI (1997) A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy 17:917\u2013928","journal-title":"Pharmacotherapy"},{"key":"534_CR10","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2165\/00002018-199309030-00003","volume":"9","author":"PN Patsalos","year":"1993","unstructured":"Patsalos PN, Duncan JS (1993) Antiepileptic drugs. A review of clinically significant drug interactions. Drug Safety 9:156\u2013184","journal-title":"Drug Safety"},{"key":"534_CR11","unstructured":"Data on file. BIAL - Portela & Ca, SA"},{"key":"534_CR12","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0731-7085(00)00232-6","volume":"22","author":"PR Ring","year":"2000","unstructured":"Ring PR, Bostick JM (2000) Validation of a method for the determination of R-warfarin and S-warfarin in human plasma using LC with UV detection. J Pharm Biomed Anal 22:573\u2013581","journal-title":"J Pharm Biomed Anal"},{"key":"534_CR13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF01065653","volume":"13","author":"DR Mungall","year":"1985","unstructured":"Mungall DR, Ludden TM, Marshall J (1985) Pharmacokinetics of racemic warfarin in adult patients. J Pharmacokinet Biopharm 13:213\u2013227","journal-title":"J Pharmacokinet Biopharm"},{"key":"534_CR14","first-page":"427","volume":"33","author":"VW Steinijans","year":"1995","unstructured":"Steinijans VW, Sauter R, Hauschke D (1995) Reference tables for the intra-subject coefficient of variation in bioequivalence studies. Int J Clin Pharmacol Ther 33:427\u2013430","journal-title":"Int J Clin Pharmacol Ther"},{"key":"534_CR15","unstructured":"EMEA\/Committee for Proprietary Medicinal Products (CPMP) (2001) Note for guidance on the investigation of bioavailability and bioequivalence. CPMP\/EWP\/1401\/98. The European Agency for the Evaluation of Medicinal Products, London"},{"key":"534_CR16","first-page":"783","volume":"63","author":"L Torr\u00e3o","year":"2007","unstructured":"Torr\u00e3o L, Costa J, Nunes T, Machado R, Soares E, Maia J, Falc\u00e3o A, Vaz-da-Silva M, Wright L, Almeida L, Soares-da-Silva P (2007) Effect of nebicapone (BIA 3\u2013202) 100 mg, 200 mg and 300 mg administered at 4-h intervals on the erythrocyte soluble catechol-O-methyltransferase (S-COMT) activity in healthy subjects. Br J Clin Pharmacol 63:783\u2013784","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-008-0534-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-008-0534-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-008-0534-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:10:49Z","timestamp":1709165449000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-008-0534-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,6]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["534"],"URL":"https:\/\/doi.org\/10.1007\/s00228-008-0534-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,6]]}}}